Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more
Getein Biotech Inc (603387) - Net Assets
Latest net assets as of September 2025: CN¥2.80 Billion CNY
Based on the latest financial reports, Getein Biotech Inc (603387) has net assets worth CN¥2.80 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.84 Billion) and total liabilities (CN¥1.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.80 Billion |
| % of Total Assets | 73.02% |
| Annual Growth Rate | 41.96% |
| 5-Year Change | 35.77% |
| 10-Year Change | 913.01% |
| Growth Volatility | 64.52 |
Getein Biotech Inc - Net Assets Trend (2012–2024)
This chart illustrates how Getein Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Getein Biotech Inc (2012–2024)
The table below shows the annual net assets of Getein Biotech Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.72 Billion | -0.74% |
| 2023-12-31 | CN¥2.74 Billion | +2.88% |
| 2022-12-31 | CN¥2.66 Billion | +17.18% |
| 2021-12-31 | CN¥2.27 Billion | +13.47% |
| 2020-12-31 | CN¥2.00 Billion | +19.17% |
| 2019-12-31 | CN¥1.68 Billion | +21.58% |
| 2018-12-31 | CN¥1.38 Billion | +20.51% |
| 2017-12-31 | CN¥1.15 Billion | +234.65% |
| 2016-12-31 | CN¥342.96 Million | +27.68% |
| 2015-12-31 | CN¥268.60 Million | +62.60% |
| 2014-12-31 | CN¥165.19 Million | +96.51% |
| 2013-12-31 | CN¥84.06 Million | +106.91% |
| 2012-12-31 | CN¥40.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Getein Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13155.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.62 Billion | 61.85% |
| Common Stock | CN¥507.15 Million | 19.36% |
| Other Comprehensive Income | CN¥280.96 Million | 10.73% |
| Other Components | CN¥211.14 Million | 8.06% |
| Total Equity | CN¥2.62 Billion | 100.00% |
Getein Biotech Inc Competitors by Market Cap
The table below lists competitors of Getein Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Indika Energy Tbk
JK:INDY
|
$322.80 Million |
|
Zhangjiagang Zhonghuan Hailu High-End Equipment Co. Ltd.
SHE:301040
|
$322.87 Million |
|
Hana Materials Inc
KQ:166090
|
$322.94 Million |
|
Reway Group S.p.A.
F:IR0
|
$322.94 Million |
|
GuangDong Rifeng Electric Cable Co Ltd
SHE:002953
|
$322.70 Million |
|
Nok Airlines Public Company Limited
OTCGREY:NOKFF
|
$322.70 Million |
|
JOY CITY PPTY HD -10
F:HKP
|
$322.69 Million |
|
Chongqing Machinery & Electric Co. Ltd
F:CE3
|
$322.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Getein Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,559,323,416 to 2,618,960,854, a change of 59,637,438 (2.3%).
- Net income of 223,636,488 contributed positively to equity growth.
- Dividend payments of 110,979,362 reduced retained earnings.
- Other comprehensive income increased equity by 275,094,052.
- Other factors decreased equity by 328,113,740.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥223.64 Million | +8.54% |
| Dividends Paid | CN¥110.98 Million | -4.24% |
| Other Comprehensive Income | CN¥275.09 Million | +10.5% |
| Other Changes | CN¥-328.11 Million | -12.53% |
| Total Change | CN¥- | 2.33% |
Book Value vs Market Value Analysis
This analysis compares Getein Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 57.23x to 1.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.15 | CN¥8.35 | x |
| 2013-12-31 | CN¥0.31 | CN¥8.35 | x |
| 2014-12-31 | CN¥0.43 | CN¥8.35 | x |
| 2015-12-31 | CN¥0.70 | CN¥8.35 | x |
| 2016-12-31 | CN¥0.90 | CN¥8.35 | x |
| 2017-12-31 | CN¥2.64 | CN¥8.35 | x |
| 2018-12-31 | CN¥4.34 | CN¥8.35 | x |
| 2019-12-31 | CN¥3.17 | CN¥8.35 | x |
| 2020-12-31 | CN¥3.61 | CN¥8.35 | x |
| 2021-12-31 | CN¥4.15 | CN¥8.35 | x |
| 2022-12-31 | CN¥4.89 | CN¥8.35 | x |
| 2023-12-31 | CN¥5.03 | CN¥8.35 | x |
| 2024-12-31 | CN¥5.15 | CN¥8.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Getein Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.54%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.20%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.42x
- Recent ROE (8.54%) is below the historical average (30.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 55.48% | 29.82% | 0.82x | 2.27x | CN¥18.00 Million |
| 2013 | 78.07% | 42.56% | 1.00x | 1.84x | CN¥57.22 Million |
| 2014 | 46.37% | 35.73% | 1.02x | 1.27x | CN¥58.93 Million |
| 2015 | 39.43% | 38.01% | 0.84x | 1.23x | CN¥78.42 Million |
| 2016 | 40.68% | 37.49% | 0.85x | 1.28x | CN¥104.35 Million |
| 2017 | 16.96% | 39.70% | 0.39x | 1.11x | CN¥79.64 Million |
| 2018 | 18.55% | 36.37% | 0.44x | 1.17x | CN¥115.08 Million |
| 2019 | 20.90% | 35.08% | 0.48x | 1.24x | CN¥177.17 Million |
| 2020 | 16.58% | 27.13% | 0.42x | 1.47x | CN¥120.93 Million |
| 2021 | 18.94% | 28.46% | 0.45x | 1.49x | CN¥188.35 Million |
| 2022 | 20.10% | 27.38% | 0.50x | 1.48x | CN¥250.66 Million |
| 2023 | 10.93% | 20.43% | 0.36x | 1.47x | CN¥23.84 Million |
| 2024 | 8.54% | 19.20% | 0.31x | 1.42x | CN¥-38.26 Million |
Industry Comparison
This section compares Getein Biotech Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,294,791,972
- Average return on equity (ROE) among peers: 19.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Getein Biotech Inc (603387) | CN¥2.80 Billion | 55.48% | 0.37x | $322.79 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $398.02 Million | 18.74% | 0.22x | $325.38 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $7.49 Billion | 23.47% | 0.34x | $2.80 Billion |
| Double Medical Technology Inc (002901) | $1.75 Billion | 26.55% | 0.28x | $399.08 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $2.85 Billion | 49.59% | 0.20x | $288.07 Million |
| Lepu Medical Tech Beijing (300003) | $16.74 Billion | 1.48% | 0.47x | $2.77 Billion |
| INKON Life Technology Co Ltd (300143) | $116.90 Million | 17.41% | 0.92x | $621.57 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $527.51 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.29 Billion | -5.53% | 0.94x | $377.92 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $105.32 Million | 39.32% | 0.45x | $271.42 Million |
| Sinocare Inc (300298) | $946.01 Million | 17.47% | 0.11x | $954.87 Million |